Drug Discovery & Development Insights by OmicsX
No Result
View All Result
  • Login
  • Register
  • Home
  • Channels
  • Startups
  • Pipeline
  • Drug Targets
  • Bio Partnering
  • Opinion
PRICING
SUBSCRIBE
  • Home
  • Channels
  • Startups
  • Pipeline
  • Drug Targets
  • Bio Partnering
  • Opinion
No Result
View All Result
Drug Discovery & Development Insights by OmicsX
No Result
View All Result
Home Big Pharma

Amgen, Inc. –
Oncology Deals and Alliances Insights

Major Oncology Deals, Collaborations & New Molecules Development Strategy

Team OmicsX by Team OmicsX
June 13, 2021
in Big Pharma, Bio Partnering, Channels, Company Profiles, Deals & Collaborations (BP), Investments & Deals, Oncology
494
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is one of the world’s largest independent biotechnology companies established at Thousand Oaks, California, in 1980.

Global Oncology Intelligence Global Oncology Intelligence Global Oncology Intelligence
Jump to section

1. Amgen Major Oncology Linked Acquisitions

  • 1. Amgen Major Oncology Linked Acquisitions
  • 2. Amgen Major Oncology Linked Deals
  • 3. Amgen Vs Other Pharma Major
  • In Mar 2021, Amgen acquired Five Prime Therapeutics in approx. $1.9 billion. Five Prime’s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer.
  • In Oct 2019, Amgen acquired 20.5% Stake in BeiGene for approx. $2.7 Billion in Cash.
  • In May 2019, Amgen, acquired Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 Mn). Nuevolution has developed Chemetics, a patent protected DNA-encoded library drug discovery platform, which enables discovery of novel small molecule drug candidates.
  • In Oct 2017, Amgen acquired Kirin-Amgen, a joint venture company in $780 Mn USD and make a wholly-owned subsidiary of Amgen. Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGEN® (epoetin alfa). Over time, the scope of the collaboration was expanded to include NEUPOGEN® (filgrastim), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Nplate® (romiplostim) and brodalumab. Kirin-Amgen holds the intellectual property for each of these products and, in exchange for royalty rights, licensed the associated marketing rights in certain Asian countries to Kyowa Hakko Kirin (KHK), Kirin’s pharmaceutical subsidiary, and in other territories to Amgen.
  • In 2013, Amgen acquired Onyx Pharmaceuticals, in $9.7 billion USD and makes it a wholly owned subsidiary.
  • In 2012, Amgen acquired Micromet, for $1.16 billion USD and makes it, its wholly owned subsidiary (named as Amgen Research (Munich) GmbH. It was developing product portfolio based on its proprietary BiTE® (Bispecific T Cell Engager) antibody platform. Micromet was in collaboration with MedImmune, for the development of new BiTE molecules targeting carcinoembryonal antigen.
  • In Mar 2011, Amgen acquired BioVex, developing OncoVEX™, an oncolytic vaccine in PH III clinical development, against melanoma in approx. $1 billion USD and makes it its wholly owned subsidiary.
  • In Apr 2006, Amgen acquired Abgenix, a biopharmaceutical company developing mAbs against cancer, for approx. $2.2 billion USD.
Jump to section

1. Amgen Major Oncology Linked Acquisitions

  • 1. Amgen Major Oncology Linked Acquisitions
  • 2. Amgen Major Oncology Linked Deals
  • 3. Amgen Vs Other Pharma Major
Page 1 of 3
Previous 123 Next
Previous Post

Hoffmann-La Roche –
Oncology Deals and Alliances Insights

Next Post

AbbVie, Inc. –
Oncology Deals and Alliances Insights

Next Post
AbbVie, Inc. – Oncology Drug Pipeline Insights – June 2021

AbbVie, Inc. –
Oncology Deals and Alliances Insights

Drug Discovery & Development Insights by OmicsX

Mapping Bio-Innovations

updated.. easy.. precise... complete...

Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.

LEARN MORE »

  • Trending
  • Comments
  • Latest
Approved Monoclonal Antibodies for Cancer Treatment

Approved Monoclonal Antibodies for Cancer Treatment

July 1, 2021
Worldwide 73 Approved Oncology Targeting Small Molecule Kinase Inhibitors

Worldwide 73 Approved Oncology Targeting Small Molecule Kinase Inhibitors

June 30, 2021

Small Molecule Kinase Inhibitors – Preclinical Drug Developers Profiles

July 1, 2021

Global Cancer Targeting Small Molecule Kinase Inhibitors in Preclinical Development – 2021

July 3, 2021
Approved Monoclonal Antibodies for Cancer Treatment

Approved Monoclonal Antibodies for Cancer Treatment

1
Cancer Targeting Clinical Stage Monoclonal Antibodies in Active Development – 2021

Cancer Targeting Clinical Stage Monoclonal Antibodies in Active Development – 2021

1
Cancer Targeting Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

Cancer Targeting Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

1
Cancer Targeting Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

Cancer Targeting Clinical Stage Bispecific Antibodies in Active Development – 2021

1
Approved Small Molecule Kinase (Non-Oncology) Inhibitors

test onco deals and alliance

May 27, 2022

Targeted Cancer Therapies in Development – Antibodies

July 1, 2021

Cancer Targeting Small Molecule Epigenetic Drugs in Development – An Overview

May 27, 2022

Global Cancer Targeting Small Molecule Epigenetic Inhibitors – 2021

June 30, 2021

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

No Result
View All Result
  • Home
  • Subscription
  • Category
    • Opinion
    • Tech
  • Landing Page
  • Buy JNews
  • Support Forum
  • Pre-sale Question
  • Contact Us

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?